Published in J Biol Chem on June 11, 2007
Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol (2009) 4.98
Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol (2012) 1.95
The fungal pattern recognition receptor, Dectin-1, and the associated cluster of C-type lectin-like receptors. FEMS Microbiol Lett (2008) 1.41
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol (2013) 0.98
Inhibitory C-type lectin receptors in myeloid cells. Immunol Lett (2010) 0.94
Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv (2013) 0.94
Maternal peripheral blood gene expression in early pregnancy and preeclampsia. Int J Mol Epidemiol Genet (2010) 0.86
Identification of natural killer cell receptor clusters in the platypus genome reveals an expansion of C-type lectin genes. Immunogenetics (2009) 0.85
Evolution of the C-type lectin-like receptor genes of the DECTIN-1 cluster in the NK gene complex. ScientificWorldJournal (2012) 0.79
Gene expression profiling reveals distinct features of various porcine adipose tissues. Lipids Health Dis (2013) 0.79
The C-type lectin-like receptors of Dectin-1 cluster in natural killer gene complex. Glycoconj J (2012) 0.77
Behçet's: A Disease or a Syndrome? Answer from an Expression Profiling Study. PLoS One (2016) 0.75
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol (2002) 9.30
The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity (2003) 5.11
IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol (2007) 2.93
NDR kinases regulate essential cell processes from yeast to humans. Nat Rev Mol Cell Biol (2006) 2.88
IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism. J Immunol (2004) 2.60
Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol (2003) 2.15
IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res (2003) 2.08
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. Curr Biol (2008) 1.75
Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J (2004) 1.73
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol (2013) 1.70
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 1.67
Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood (2005) 1.61
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS One (2007) 1.61
The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. Biochem Biophys Res Commun (2006) 1.58
Integration of activating and inhibitory receptor signaling by regulated phosphorylation of Vav1 in immune cells. Sci Signal (2011) 1.57
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (2012) 1.56
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood (2008) 1.56
Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2008) 1.47
The MST1 and hMOB1 tumor suppressors control human centrosome duplication by regulating NDR kinase phosphorylation. Curr Biol (2009) 1.43
IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2009) 1.42
Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res (2011) 1.41
Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res (2008) 1.40
Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 1.37
Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol (2011) 1.35
The TREM-1/DAP12 pathway. Immunol Lett (2007) 1.33
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother (2007) 1.30
Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One (2007) 1.26
Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol (2004) 1.25
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol (2009) 1.20
Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med (2005) 1.18
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest (2014) 1.17
Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol (2005) 1.13
Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer (2008) 1.12
Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology (2007) 1.12
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer (2009) 1.11
Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog (2011) 1.11
Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab')2. Proc Natl Acad Sci U S A (2010) 1.09
Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J Biol Chem (2004) 1.09
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
Natural killer cells and solid tumors. J Innate Immun (2011) 1.07
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood (2013) 1.06
Inhibitory receptor signals suppress ligation-induced recruitment of NKG2D to GM1-rich membrane domains at the human NK cell immune synapse. J Immunol (2007) 1.05
Non-T cell activation linker (NTAL) negatively regulates TREM-1/DAP12-induced inflammatory cytokine production in myeloid cells. J Immunol (2007) 1.05
Differential NDR/LATS interactions with the human MOB family reveal a negative role for human MOB2 in the regulation of human NDR kinases. Mol Cell Biol (2010) 1.04
Fine-tuning of immune responses by SLAM-related receptors. J Leukoc Biol (2005) 1.01
Regulation of 2B4 (CD244)-mediated NK cell activation by ligand-induced receptor modulation. Eur J Immunol (2006) 1.01
2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol (2006) 1.00
Memory of infections: an emerging role for natural killer cells. PLoS Pathog (2013) 1.00
Cutting edge: NTB-A activates NK cells via homophilic interaction. J Immunol (2004) 0.99
The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. J Biol Chem (2012) 0.98
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology (2009) 0.97
Ablation of the kinase NDR1 predisposes mice to the development of T cell lymphoma. Sci Signal (2010) 0.97
Natural killer cells: fighting viruses and much more. Nat Immunol (2011) 0.96
Regulation of NK cell activity by 2B4, NTB-A and CRACC. Front Biosci (2008) 0.96
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int (2010) 0.96
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother (2009) 0.96
Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood (2013) 0.96
Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon. J Immunol (2006) 0.95
TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest (2004) 0.95
Comprehensive analysis of NK cell function in whole blood samples. J Immunol Methods (2008) 0.94
CD48 stimulation by 2B4 (CD244)-expressing targets activates human NK cells. J Immunol (2006) 0.94
Modulation of 2B4 (CD244) activity and regulated SAP expression in human NK cells. Eur J Immunol (2007) 0.92
Regulation of NK cell function by human granulocyte arginase. J Immunol (2009) 0.92
Glycosylation affects ligand binding and function of the activating natural killer cell receptor 2B4 (CD244) protein. J Biol Chem (2011) 0.92
Regulatory T cells control macrophage accumulation and activation in lymphoma. Int J Cancer (2010) 0.91
Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther (2013) 0.89
Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol (2009) 0.89
Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int J Cancer (2007) 0.89
Btk is a positive regulator in the TREM-1/DAP12 signaling pathway. Blood (2011) 0.88
The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res (2006) 0.88
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine (2009) 0.87
The use of trimeric isoleucine-zipper fusion proteins to study surface-receptor-ligand interactions in natural killer cells. J Immunol Methods (2004) 0.87
2-D DIGE analyses of enriched secretory lysosomes reveal heterogeneous profiles of functionally relevant proteins in leukemic and activated human NK cells. Proteomics (2008) 0.87
A unique secreted adenovirus E3 protein binds to the leukocyte common antigen CD45 and modulates leukocyte functions. Proc Natl Acad Sci U S A (2013) 0.86
Molecular analysis of NTB-A signaling: a role for EAT-2 in NTB-A-mediated activation of human NK cells. J Immunol (2006) 0.86
2B4 engagement mediates rapid LFA-1 and actin-dependent NK cell adhesion to tumor cells as measured by single cell force spectroscopy. J Immunol (2011) 0.85
Glycosylation analysis of interleukin-23 receptor: elucidation of glycosylation sites and characterization of attached glycan structures. J Mass Spectrom (2010) 0.85
Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity. Clin Immunol (2009) 0.85
Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res (2009) 0.85
The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction. Cytokine Growth Factor Rev (2012) 0.83
NF-κ B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. Int J Cancer (2011) 0.83
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer (2012) 0.82
CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells. J Immunol (2014) 0.82
NAB2 and EGR-1 exert opposite roles in regulating TRAIL expression in human Natural Killer cells. Immunol Lett (2013) 0.81
Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP. Mol Immunol (2007) 0.81
WF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells. J Biomed Biotechnol (2011) 0.81
C17 prevents inflammatory arthritis and associated joint destruction in mice. PLoS One (2011) 0.81
Toward the next generation of NK cell-based adoptive cancer immunotherapy. Oncoimmunology (2013) 0.80